You are here: Welcome » Marc Girardot

Marc Girardot

Career

2008 CV - Marc Girardot is managing director of the Global Automotive Practice in the Cisco Internet Business Solutions Group (IBSG). As a core team member of IBSG’s Manufacturing senior staff, he provides strategic assistance to car manufacturers and to related organizations looking to capitalize on the transformative power of the Internet.

Girardot consults with senior executives from the auto industry and coordinates Cisco’s global efforts to accelerate the adoption of enabling technologies to transform the industry. Girardot has more than 15 years of industry and consulting experience working for leading corporations across the globe.

Before coming to Cisco, he was senior associate for Booz Allen Hamilton’s Communications Media and Technology Group. He also has extensive experience in the oil and gas industry, where he consulted for British Petroleum, Exxon, and Elf. Prior to his consulting years, Girardot held a variety of management positions in sales, management accounting, auditing, and strategy for industrial gas leader Air Liquide. Girardot holds an MBA from INSEAD, France, and a master’s degree in economics from ESSEC, France 1)

June 2021 Biz News Article

Natural immunity vs Covid-19 vaccine-induced immunity – Marc Girardot of PANDA 28th June 2021 by Nadya Swart

Covid-19 brought about an age of misinformation like never before. With this, the responsibility of journalists to provide informed, well-researched and objective news to the public has never been of more paramount importance. This article by Marc Girardot, a member of PANDA, is loaded with hyperlinks – each of which provide the source of those facts asserted in the article. The links and pictures are an integral part of this article, which takes a deep dive into the issue of natural immunity and Covid-19 vaccination. This article is not and should not be construed as ‘anti-vax’. Rather, it provides evidence of natural immunity. It is impeccably researched and well worth reading. – Nadya Swart

Should people who have recovered from COVID take a vaccine?

Epidemiology, immunology and the clinical data all say a clear “No!”. There is no good reason to vaccinate the recovered.

By Marc Girardot 2)

July 2021 Biz News Interview

Natural immunity vs vaccine-induced immunity: An interview with Marc Girardot of PANDA 23rd July 2021 by Nadya Swart

In this interview, Girardot talks extensively about the fallacies surrounding asymptomatic transmission and the waning natural immunity of those who have recovered from Covid-19. Having worked closely with cancer vaccines in Paris, the strategy consultant had particularly interesting insights into the ‘vaccine race’. While Girardot believes that the vaccine is a fantastic advancement, he has some concerns. The power of natural immunity against viral infections is thoroughly explored, with Girardot stating that ‘evolution has done things perfectly.’ For ease of understanding, concise explanations of technical terms in the interview are set out below the excerpts taken from the interview. – Nadya Swart 3)

Oct 2021 iHeart Radio Interview

Marc Girardot: Super-Immunity, Medical Freedom and the Great Reset October 26, 2021 • 117 min

Marc is a French-American father of four children who has spent his career in the world of tech and biotech. He holds an MBA from INSEAD, as well as a masters in Economics and Business from ESSEC. He has deep experience in innovation and complex systems, working for Cisco, Booz Allen and Air Liquide. A seasoned strategy consultant trained in the scientific method with experience in Automotive, Biotech and Energy, Marc is a regular lecturer and keynote speaker at leading business schools and corporations. In recent years, Marc has supported a promising anti-cancer DNA vaccine company.

  • JOIN US AS WE EXPLORE:
  • Marc unpacks the multiple factors that transformed a virus into political and medical madness
  • Marc’s first red flag that took him down his COVID journey– “where are all the deaths?”
  • What super-immunity is and its relation to the large “asymptomatic” numbers
  • The critical danger of negating the power of natural fever with medications
  • The failure of the COVID vaccine so address the root cause of severe illness
  • Why not wanting to take the COVID vaccine does not make you “anti-vax”
  • Vaccine induced COVID
  • The health danger of the vaccine from administration to toxic spike protein
  • Why natural immunity is superior to vaccine immunity
  • The truth of healthy children’s risk to COVID – spoiler there is none
  • And much much more demystifying of the COVID narrative. 4)

Pandemic PANDA

Substack Covid Mythbuster

Panda member / Critical Thinker / Citizen scientist Author of multiple breakthrough articles on Covid Senior advisor in Bio and Auto 5)

Pandemic Research Criticism

Marc Girardot is a tech guy turned COVID-19 contrarian. His analogy to falsely “explain” why mRNA vaccines are deadly shows an astounding lack of understanding of basic chemistry.

By Orac Post date February 25, 2022

Like far too many tech guys with no discernible serious expertise in public health, virology, infectious disease, molecular biology, or other relevant disciplines to comment on COVID-19, public health, and vaccines, Girard nonetheless does not let a little thing like his lack of relevant expertise stop him, as evidenced by his Substack (where all the quacks now go), Covid Myth Buster Series, which, he brags, debunks “the COVID narrative, with observation, facts, data, and rigorous scientific method.”

Unfortunately, Girardot’s braggadocio notwithstanding, apparently his “facts, data, and rigorous scientific method” don’t include an understanding of basic chemistry, if his post What happens to those billions of NanoParticles you’ve become host to? is any indication. Either that, or he knows basic chemistry but is simply intentionally using the fact that most people don’t understand a lot of basic chemistry and, as a result, will find his analogy frightening because of all the big numbers to fear monger in a manner that, to this old chemistry major, made me laugh out loud with contempt. 6)

Educated Guess for Giradot's Client & Unnamed Cancer Vaccine Reference

Founded in 2010 out of the Pasteur Institute, Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancer with its headquarters in Houston, Texas and Research & Innovation center in Paris.

Invectys exploits a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two platforms: 1) HLA-G, a powerful immune checkpoint and a tumor specific antigen; 2) the universal tumor antigen telomerase (TERT) that is critical to uncontrolled cell growth.

Traditional vaccination aims at injecting an antigen into a receiver, to trigger an immune response against this antigen and set up immunological memory. The goal of DNA vaccination is instead to inject the antigen’s DNA, making the receiver’s body produce the antigen. Upon receiving the DNA vaccine, Antigen Presenting Cells (APCs) will produce the antigen corresponding to the DNA, and present it to other immune cells like it would in the case of a usual infection.

Typically, the vaccinating DNA is integrated into plasmids, which are circular strands of DNA used by bacteria in addition to their chromosomal genetic material. The plasmids are then injected to the patient intradermally (through the skin), and find their way into the nucleus of various patient’s cells, including APCs. The DNA carried by the plasmid will not fuse with the patient’s chromosomes, but will still be translated into proteins by the cellular machinery. Thus, the APC will start expressing the antigen encoded by the plasmid, and present it to the immune system to trigger a specific response.

DNA vaccination is a technology with many advantages compared to conventional approaches. The antigen is produced by the patient’s cells, allowing for post-translation modifications to occur, and presented by both MHC class I and II to generate cell-mediated and humoral immune responses. DNA vaccination allows a polarization of the T helper response towards Th1 or Th2. Additionally, there is no need for the costly laboratory production and purification of recombinant proteins, making DNA-based products easy to produce, stable over time and cost effective.

In oncology, the purpose of DNA vaccines is to induce the production of cancer-specific antigens in the patient’s body. Specialized Antigen Presenting Cells (APCs) will then activate the appropriate immune responses. This allows the patient’s immune system to target and destroy cancer cells. Invectys’ IVS-2001, uses this technology to induce an immune response to telomerase peptides.

The vaccine is administered via needle-free injection for minimal patient discomfort.7)

Back to top